Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATALYST COVID-19 multi-arm phase II trial
2020-001684-89Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemtuzumab ozogamicin, namilumab and infliximab in coronavirus disease 2019 (COVID-19) and Viral lower respiratory tract infection (VLRTI) (4 arms), sponsored by University of Birmingham. Status: unknown.
02
Drugs
gemtuzumab ozogamicinnamilumabinfliximab
03
Conditions
coronavirus disease 2019 (COVID-19)Viral lower respiratory tract infection (VLRTI)
Beyond the preview
Go deeper on 2020-001684-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001684-89.